Most human diseases are caused by dysfunction of interacting pathways of proteins or single proteins. Understanding and identifying the proteomic fingerprint of a disease and thereby identifying very specific and reliable drug targets is fundamental to highly efficient and successful drug discovery and development. This is to understand a disease at the molecular level.

The proteomic fingerprint of a disease found in animal models of human diseases corresponds poorly to the proteomic fingerprint of the same diseases in humans.

We produce a comprehensive proteomic fingerprint of a disease on basis of diseased and healthy human small (fine needle) biopsies. These biopsies are maintained in our proprietary Bioreactor for several days in order to eliminate stress or apoptosis-related protein expression.

Our proprietary technologies and know-how allow us to detect, quantitate and identify proteins and peptides at unsurpassed high resolution and sensitivity. We are able to detect more than 99% of all soluble proteins and peptides from as few as a few thousand cells or a 0.5mm³ biopsy.

Download PDF Presentation: DrugMode Drug Target Identification